FDA: Many post-market studies have not begun

04/24/2008 | Bloomberg1

A federal report found that drugmakers, as of Sept. 30, had not begun 1,044 post-market drug studies that they agreed to perform. An industry official said studies can be delayed because of conversations with the agency over their design, as well as difficulty recruiting patients. An FDA spokeswoman said the agency will make sure drug firms finish the incomplete post-approval trials "in a timely manner."

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC